LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1018

Search options

  1. Article: Moving apart together: co-movement of a symbiont community and their ant host, and its importance for community assembly.

    Parmentier, T / Claus, R / De Laender, F / Bonte, D

    Movement ecology

    2021  Volume 9, Issue 1, Page(s) 25

    Abstract: Background: Species interactions may affect spatial dynamics when the movement of one species is determined by the presence of another one. The most direct species-dependence of dispersal is vectored, usually cross-kingdom, movement of immobile ... ...

    Abstract Background: Species interactions may affect spatial dynamics when the movement of one species is determined by the presence of another one. The most direct species-dependence of dispersal is vectored, usually cross-kingdom, movement of immobile parasites, diseases or seeds by mobile animals. Joint movements of species should, however, not be vectored by definition, as even mobile species are predicted to move together when they are tightly connected in symbiont communities.
    Methods: We studied concerted movements in a diverse and heterogeneous community of arthropods (myrmecophiles) associated with red wood ants. We questioned whether joint-movement strategies eventually determine and speed-up community succession.
    Results: We recorded an astonishingly high number of obligate myrmecophiles outside red wood ant nests. They preferentially co-moved with the host ants as the highest densities were found in locations with the highest density of foraging red wood ants, such as along the network of ant trails. These observations suggest that myrmecophiles resort to the host to move away from the nest, and this to a much higher extent than hitherto anticipated. Interestingly, functional groups of symbionts displayed different dispersal kernels, with predatory myrmecophiles moving more frequently and further from the nest than detritivorous myrmecophiles. We discovered that myrmecophile diversity was lower in newly founded nests than in mature red wood ant nests. Most myrmecophiles, however, were able to colonize new nests fast suggesting that the heterogeneity in mobility does not affect community assembly.
    Conclusions: We show that co-movement is not restricted to tight parasitic, or cross-kingdom interactions. Movement in social insect symbiont communities may be heterogeneous and functional group-dependent, but clearly affected by host movement. Ultimately, this co-movement leads to directional movement and allows a fast colonisation of new patches, but not in a predictable way. This study highlights the importance of spatial dynamics of local and regional networks in symbiont metacommunities, of which those of symbionts of social insects are prime examples.
    Language English
    Publishing date 2021-05-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 2724975-X
    ISSN 2051-3933
    ISSN 2051-3933
    DOI 10.1186/s40462-021-00259-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Restoring Immune Mediated Disease Control by Ipilimumab Re-exposition in a Heavily pretreated Patient With MSI-H mCRC.

    Jordan, Frank / Trepel, Martin / Claus, Rainer

    Clinical colorectal cancer

    2022  Volume 21, Issue 3, Page(s) e148–e151

    Abstract: Background: Immune-Checkpoint-inhibitors (ICIs) are approved in first line therapy of microsatellite-instable, deficient miss-match-repair (MSI-H-dMMR) metastatic colorectal cancer (mCRC), and in second line after standard chemotherapy. Evidence ... ...

    Abstract Background: Immune-Checkpoint-inhibitors (ICIs) are approved in first line therapy of microsatellite-instable, deficient miss-match-repair (MSI-H-dMMR) metastatic colorectal cancer (mCRC), and in second line after standard chemotherapy. Evidence supporting immunotherapy after immunotherapy is scarce.
    Case report: This case report highlights the course of a heavily pretreated patient with MSI-H mCRC with progression after multiple local therapies, standard chemotherapies and pembrolizumab. After 4 cycles of ipilimumab and nivolumab followed by nivolumab-maintenance he achieved a long-lasting disease control of 22 months. After further subsequent progression he regained immune mediated disease control by a second "boost" of ipilimumab.
    Conclusion: Re-exposition with ipilimumab is a potential option to restore immune-mediated-disease-control in patients with preceding long-lasting response to ipilimumab/nivolumab and with dMMR-tumors. The clinical situation of progress after long-lasting disease control on ICIs becomes more common and is an opportunity to investigate potential strategies for restoring immune mediated disease control.
    MeSH term(s) Colonic Neoplasms/drug therapy ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; DNA Mismatch Repair ; Humans ; Immunotherapy ; Ipilimumab/pharmacology ; Ipilimumab/therapeutic use ; Male ; Microsatellite Instability ; Nivolumab/therapeutic use
    Chemical Substances Ipilimumab ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2022-01-08
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2112638-0
    ISSN 1938-0674 ; 1533-0028
    ISSN (online) 1938-0674
    ISSN 1533-0028
    DOI 10.1016/j.clcc.2022.01.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Vielversprechende neue Behandlungsoption für ältere Patienten mit akuter myeloischer Leukämie

    Claus, Rainer

    Karger Kompass Onkologie

    2018  Volume 5, Issue 2, Page(s) 98–99

    Abstract: Background: Elderly patients (aged ≥65 years) with acute myeloid leukaemia have poor outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating agents such as azacitidine and decitabine is common, but responses are modest ... ...

    Institution II. Medizinische Klinik, Klinikum Augsburg, Augsburg, Deutschland
    Abstract Background: Elderly patients (aged ≥65 years) with acute myeloid leukaemia have poor outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating agents such as azacitidine and decitabine is common, but responses are modest and typically short-lived. The oral anti-apoptotic B-cell lymphoma 2 protein inhibitor, venetoclax, has shown promising single-agent activity in patients with relapsed or refractory acute myeloid leukaemia and preclinical data suggested synergy between hypomethylating agents and venetoclax, which led to this combination phase 1b study. Methods: Previously untreated patients aged 65 years and over with acute myeloid leukaemia who were ineligible for standard induction therapy were enrolled into this non-randomised, open-label, phase 1b study. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0-2 and either intermediate-risk or poor-risk cytogenetics. Patients were enrolled into one of three groups for the dose-escalation phase of this study: group A (venetoclax and intravenous decitabine 20 mg/m2 [days 1-5 of each 28-day cycle]), group B (venetoclax and subcutaneous or intravenous azacitidine 75 mg/m2 [days 1-7 of each 28-day cycle]), and group C (a venetoclax and decitabine substudy with the oral CYP3A inhibitor posaconazole, 300 mg twice on cycle 1, day 21, and 300 mg once daily from cycle 1, days 22-28, to assess its effect on venetoclax pharmacokinetics). Dose escalation followed a standard 3 + 3 design with at least three evaluable patients enrolled per cohort; daily target doses of venetoclax for groups A and B were 400 mg (cohort 1), 800 mg (cohorts 2 and 3), and 1200 mg (cohort 4), and 400 mg for group C. The primary endpoints were the safety and pharmacokinetics of venetoclax plus decitabine or azacitidine, and to determine the maximum tolerated dose and recommended phase 2 dose. Secondary endpoints included the preliminary anti-leukaemic activity of venetoclax with decitabine or azacitidine through the analysis of overall response, duration of response, and overall survival. We analysed safety, pharmacokinetics, and anti-leukaemic activity in all patients who received one or more venetoclax doses. The expansion phase of the study is ongoing but is closed to accrual. This trial is registered with ClinicalTrials.gov, number NCT02203773. Findings: 57 patients were enrolled in the study. 23 patients in group A and 22 patients in group B were enrolled between Nov 19, 2014, and Dec 15, 2015, and 12 patients in group C were enrolled between June 14, 2015, and Jan 16, 2016. As of data cutoff on June 15, 2016, the most common grade 3-4 treatment-emergent adverse events were thrombocytopenia (27 [47%] of 57 patients; nine in group A, 13 in group B, and five in group C), febrile neutropenia (24 [42%] of 57; 11 in group A, ten in group B, and three in group C), and neutropenia (23 [40%] of 57; 12 in group A, eight in group B, and three in group C). The most common serious treatment-emergent adverse event in groups A and B was febrile neutropenia (seven [30%] of 23 patients vs seven [32%] of 22), whereas in group C it was lung infection (four [33%] of 12 patients). 49 (86%) of 57 patients had treatment-related adverse events; the most common in groups A and B included nausea (12 [52%] patients vs seven [32%] patients), fatigue (six [26%] patients vs seven [32%]), and decreased neutrophil count (six [26%] patients vs six [27%]), whereas in group C the most common were nausea (seven [58%] of 12 patients), leucopenia (six [50%]), vomiting (five [42%]), and decreased platelet count (five [42%]). The maximum tolerated dose was not reached. The recommended phase 2 dose was 400 mg once a day or 800 mg with an interrupted dosing schedule (safety expansion). In total, four (7%) of 57 patients had died within 30 days of the first venetoclax dose caused by sepsis (group B), bacteraemia (group A), lung infection (group C), and respiratory failure (group A). Tumour lysis syndrome was not observed. Decitabine and azacitidine did not substantially affect venetoclax exposures. Overall, 35 (61%; 95% CI 47 · 6-74 · 0) of 57 patients achieved complete remission or complete remission with incomplete marrow recovery. In groups A and B, 27 (60%; 95% CI 44 · 3-74 · 3) of 45 patients had complete remission or complete remission with incomplete marrow recovery. Interpretation: Venetoclax plus hypomethylating agent therapy seems to be a novel, well-tolerated regimen with promising activity in this underserved patient population. Evaluation of expansion cohorts is ongoing at 400 mg and 800 mg doses using both hypomethylating agent combinations. Funding: AbbVie and Genentech.
    Language English
    Publishing date 2018-04-12
    Publisher S. Karger GmbH
    Publishing place Freiburg, Germany
    Document type Article
    Note Wissenstransfer
    ZDB-ID 3050162-3
    ISSN 2296-5386 ; 2296-5416
    ISSN (online) 2296-5386
    ISSN 2296-5416
    DOI 10.1159/000487766
    Database Karger publisher's database

    More links

    Kategorien

  4. Article: Ein neuer Therapiestandard für die Behandlung des follikulären Lymphoms in frühen Stadien?

    Claus, Rainer

    Karger Kompass Onkologie

    2018  Volume 5, Issue 4, Page(s) 233–235

    Abstract: Das follikuläre Lymphom (FL) im Stadium I und II nach Ann Arbor kann lokal durch Involved-field-Strahlentherapie (IFRT) in kurativer Intention behandelt werden. Eine aktuell in der Fachzeitschrift «Journal of Clinical Oncology» publizierte Arbeit ... ...

    Institution II. Medizinische Klinik, Klinikum Augsburg, Augsburg, Deutschland
    Abstract Das follikuläre Lymphom (FL) im Stadium I und II nach Ann Arbor kann lokal durch Involved-field-Strahlentherapie (IFRT) in kurativer Intention behandelt werden. Eine aktuell in der Fachzeitschrift «Journal of Clinical Oncology» publizierte Arbeit adressiert nun die Frage, ob die Hinzunahme einer systemischen Chemo(immun)- therapie zur IFRT eine Verbesserung der Prognose bewirkt. In der TROG 99.03-Studie wurden insgesamt 150 Patienten mit FL im Stadium I oder II randomisiert und entweder nur mit 30 Gy IFRT oder mit 30 Gy IFRT plus 6 Zyklen Systemtherapie mit Cyclophosphamid, Vincristin und Prednison ohne (CVP) oder mit Rituximab (R-CVP) behandelt. Nach einem medianen Follow-up von knapp 10 Jahren zeigte sich eine signifikante Überlegenheit im progressionsfreien Überleben (PFS) für Patienten unter der kombinierten Radiochemotherapie gegenüber der alleinigen IFRT (Hazard Ratio (HR) = 0,57; 95%-Konfidenzintervall (KI) = 0,34-0,95; p = 0,033). Das 10-Jahres-PFS lag im Kombinationsarm bei 59% gegenüber 41% im IFRT-Arm. Der PFS-Vorteil war noch deutlicher ausgeprägt bei Patienten, die zusätzlich Rituximab im Rahmen der Kombinationstherapie erhielten (HR = 0,26; 95%-KI = 0,07-0,97; p = 0,045). Das Gesamtüberleben (OS) war mit einem 10-Jahres-OS von 95% für Patienten unter kombinierter Therapie gegenüber 86% unter alleiniger IFRT (p = 0,40) nicht signifikant unterschiedlich. Der frühe Einsatz von Systemtherapie im Kombinationsarm führte jedoch zu einer Verminderung des Risikos für eine Transformation in aggressive Lymphome. Unter Bestrahlung zeigte ein Großteil der Patienten in beiden Therapiearmen Grad 1-2 Toxizitäten, höhergradige Nebenwirkungen waren im IFRT-Arm extrem selten (2% der Patienten). Demgegenüber traten Grad 3-4 Toxizitäten wie Neutropenien, Infektionen, Diarrhoe, Fatigue, febrile Neutropenien und Spättoxizitäten wie Polyneuropathie unter Kombinationstherapie deutlich häufiger auf. Die Autoren um Michael MacManus schlussfolgerten, dass die kombinierte Therapie aus IFRT und Chemoimmuntherapie effektiver für die Behandlung von FL im Frühstadium ist und somit einen möglichen neuen Behandlungsstandard darstellen könnte.
    Language German
    Publishing date 2018-11-08
    Publisher S. Karger GmbH
    Publishing place Freiburg, Germany
    Document type Article
    Note Wissenstransfer
    ZDB-ID 3050162-3
    ISSN 2296-5386 ; 2296-5416
    ISSN (online) 2296-5386
    ISSN 2296-5416
    DOI 10.1159/000493375
    Database Karger publisher's database

    More links

    Kategorien

  5. Book ; Thesis: Extrazellulärer Sphingolipidmetabolismus bei systemischer Inflammation

    Claus, Ralf

    2008  

    Author's details von Ralf Alexander Claus
    Language German ; English
    Size Getr. Zählung : Ill., graph. Darst.
    Publishing country Germany
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Jena, Univ., Habil.-Schr., 2008
    Note Enth. Sonderabdr. - Beitr. teilw. dt., teilw. engl.
    HBZ-ID HT018716347
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  6. Article ; Online: A refined method for theory-based evaluation of the societal impacts of research

    Belcher, B. / Davel, R. / Claus, R.

    2021  

    Keywords evaluation ; research ; impact assessment
    Language English
    Publishing date 2021-03-08T08:14:49Z
    Publisher Elsevier
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Leading inter- and transdisciplinary research

    Deutsch, L. / Belcher, B. / Claus, R. / Hoffmann, S.

    Environmental Science & Policy

    Lessons from applying theories of change to a strategic research program

    2021  

    Abstract: Theory of Change (ToC) has been promoted as a useful tool in sustainability research for visioning, planning, communication, monitoring, evaluation and learning. It involves a mapping of steps towards a desired long-term goal supplemented with continuous ...

    Abstract Theory of Change (ToC) has been promoted as a useful tool in sustainability research for visioning, planning, communication, monitoring, evaluation and learning. It involves a mapping of steps towards a desired long-term goal supplemented with continuous reflection on how and why change is expected to happen in a particular context. However, there is limited reported experience with the development and application of ToCs in inter- and transdisciplinary research contexts. While some previous publications have focused on ex-post application, there has been little discussion about the process of developing and using ToCs in strategic planning and monitoring in large inter- and transdisciplinary research programs. This article reports challenges and lessons learned from the experience of developing and using ToCs in the inter- and transdisciplinary research program Wings (Water and sanitation innovations for non-grid solutions). Challenges include (1) managing time constraints, (2) balancing between concrete and abstract discussions, (3) ensuring diversity in group composition, (4) fluctuating between reservations and appreciation, and (5) fulfilling both service and science roles while leading the ToC process. The experience highlights the importance of alternating formal and informal interaction formats throughout the process, ensuring heterogenous group formation, involving early career scientists, being responsive to emergent needs and making the added value of developing and using ToCs explicit and tangible for all participants. Although these lessons are mainly derived from developing ToCs within the interdisciplinary program team, they can support other programs in both their inter- and transdisciplinary research endeavors.
    Keywords research ; monitoring ; evaluation
    Language English
    Publishing date 2021-05-07T06:13:36Z
    Publisher Elsevier
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Book ; Online: Evaluation Report. Oil Palm Portfolio. An Outcome Evaluation of FTA’s Research Portfolio on Oil Palm

    Davel, R. / Claus, R. / Ichsan, M. / Belcher, B.

    2021  

    Abstract: This report assesses the project design, implementation, and outcome realization of FTA’s research portfolio on oil palm in Indonesia. Four projects from the portfolio were selected for in-depth assessment: Supporting Local Regulations for Sustainable ... ...

    Abstract This report assesses the project design, implementation, and outcome realization of FTA’s research portfolio on oil palm in Indonesia. Four projects from the portfolio were selected for in-depth assessment: Supporting Local Regulations for Sustainable Oil Palm in East Kalimantan (EK), Governing Oil Palm Landscapes for Sustainability (GOLS), Oil Palm Adaptive Landscapes (OPAL), and Engendering RSPO Standards (ERS). The report documents and empirically tests whether and how intended portfolio outcomes were realized, with specific attention to the characteristics of projects’ design and implementation that contributed to changes in policy and practice within Indonesia’s oil palm sector.
    Keywords oil palms
    Language English
    Publishing date 2021-03-29T10:55:19Z
    Publisher The CGIAR Research Program on Forests, Trees and Agroforestry
    Publishing country fr
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Book ; Online: Die Entwickelung des Bankwesens in Russland

    Claus, Rudolf

    (Kapitel 1 u. 2.)

    2017  

    Title variant Entwicklung
    Author's details von Rudolf Claus
    Language German
    Dates of publication 2017-1907
    Size 1 Online-Ressource (56 Seiten)
    Publisher ZBW
    Publishing place Kiel ; Hamburg
    Document type Book ; Online
    Database ECONomics Information System

    More links

    Kategorien

  10. Article ; Online: Sarcoidosis mimicking nodal manifestations of marginal zone lymphoma.

    Enke, Johanna S / Reitsam, Nic G / Schaller, Tina / Claus, Rainer / Lapa, Constantin / Dierks, Alexander

    European journal of nuclear medicine and molecular imaging

    2023  Volume 50, Issue 10, Page(s) 3151–3152

    MeSH term(s) Humans ; Lymphoma, B-Cell, Marginal Zone/diagnostic imaging ; Lymphoma, B-Cell, Marginal Zone/pathology ; Lymph Nodes/pathology ; Sarcoidosis/diagnostic imaging
    Language English
    Publishing date 2023-04-26
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 8236-3
    ISSN 1619-7089 ; 0340-6997 ; 1619-7070
    ISSN (online) 1619-7089
    ISSN 0340-6997 ; 1619-7070
    DOI 10.1007/s00259-023-06237-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top